Connect Biopharma Holdings Limited has announced the initiation of its Phase 2 Seabreeze STAT Asthma study, which aims to evaluate the safety and efficacy of rademikibart in treating acute ...

The introduction of biologic therapies for severe asthma has transformed clinical practice. Among these agents, benralizumab ...

Only 15% of patients were adherent to ICS therapy 3 months after their asthma exacerbation, and less that one-fourth of those remained adherent 9 months later. Improved adherence to inhaled ...

Infections, not eosinophilic inflammation, are the primary cause of asthma exacerbations in patients receiving benralizumab.

The introduction of respiratory biologics shows greatest benefits in patients with severe and eosinophilic asthma.

Dupilumab significantly reduced the risk of exacerbations compared with placebo in children with moderate to severe asthma, regardless of exacerbation history. Dupilumab was shown to consistently ...

For patients with severe asthma with an eosinophilic phenotype, depemokimab reduces the annualized rate of exacerbations, according to a study published online Sept. 9 in the New England Journal of ...

Please provide your email address to receive an email when new articles are posted on . Moderate exacerbations shared similar characteristics with severe exacerbations. Lung function, limitations and ...

The study’s investigators suggest the results in this patient population may indicate rises in clinically diagnosed viral infections from viruses other than SARS-CoV-2 following pandemic lockdown ...

The ultra-long acting investigational biologic is administered once every 6 months as a subcutaneous injection. Depemokimab reduced the rate of exacerbations in patients with severe asthma with type 2 ...

Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with a lower risk for acute asthma exacerbations in adolescents with overweight or obesity, according to a research letter ...

In acute exacerbations of asthma, corticosteroids remain the mainstay of anti‐inflammatory therapy. Systemic agents such as prednisolone or methylprednisolone are introduced promptly—often ...